Compare GSK plc (GSK) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.22 (market cap $17.89B). The key difference: GSK plc is far larger — about 5.1× iShares iBoxx $ High Yield Corporate Bond ETF's market cap, and GSK plc pays a 3.9% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days on average.
| GSK | HYG | |
|---|---|---|
Market Cap | $91.88B | $17.89B |
Volume | 7,730,529 | 44,866,592 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $81.28 |
52-Week Low | $43.24 | $76.90 |
Typical Hold Time | 93 Days | 60 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
HYG trades at $77.205, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though RSI suggests potential oversold conditions. The ETF maintains regular dividend distributions, with recent payouts ranging from $0.38 to $0.44. Market focus remains on high-yield bond performance amid rising Treasury yields and Federal Reserve policy uncertainty.
The outlook for HYG remains challenged by persistent bond market volatility and rising interest rates. While the fund's consistent dividend payments provide income support, the bearish technical setup and macroeconomic headwinds suggest continued pressure on high-yield corporate bonds. Investors face risks from credit quality deterioration and duration exposure in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
